AP NEWS
Click to copy
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

LexaGene Will Host a Free Webinar Providing an Overview of the Company

June 6, 2019

BEVERLY, Mass., June 06, 2019 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., ( OTCQB: LXXGF; TSX-V: LXG ) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announce that LexaGene will host a webinar today, Thursday, June 6 at 11 AM EST to provide an investor focused overview of the Company.

This investor focused webinar will cover:

-- Recent progress of LexaGene -- Market opportunity -- Beta product over-view -- The LexaGene Team -- Future plans for LexaGene

Dr. Jack Regan, LexaGene’s Chief Executive Officer, will be leading the webinar and answering questions live.

The webinar signup can be accessed for free at this link.

To be added to the LexaGene email distribution list, please subscribe on the Company website.

About LexaGene Holdings Inc.LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, and press ‘go’. The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can process multiple samples at a time, in an on-demand fashion, returning results in about 1 hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

Media Contacts Nicole Ridgedale Director of Corporate Marketing, LexaGene800.215.1824 ext. 206 nridgedale@lexagene.com

Investor Relations Jay AdelaarVice President of Capital Markets, LexaGene800.215.1824 ext. 207 jadelaar@lexagene.com

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors – including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues – that could cause actual results to differ materially from the Company’s expectations as disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com ). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

All contents © copyright 2019 The Associated Press. All rights reserved.